Vascular complications of type 2 diabetes mellitus beyond the reach of glycemic control
https://doi.org/10.14341/2072-0351-5498
Abstract
Current therapeutic strategies of type 2 diabetes mellitus are aimed at reducing the risk of acute and late vascular complications by means of normalizationof glycemia, improvement of life quality and expectancy, minimization of socio-economic losses. The adequate glycemic control should besupplemented by screening for and correction of risk factors of cardiovascular disorders; it may help to prevent or delay the development of macrovascularcomplications.
About the Author
Tatiana Yul'evna Demidova
ГОУ ДПО Российская медицинская академия последипломного образования, Москва
References
1. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2003. - 348. - Р. 383-393 and 358. - Р. 580-591, 2008.
2. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2008. - 358. - Р. 580-591.
3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications // Nature. - 2001. - 414. - Р. 813-820.
4. Caballero A.E. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease // Obesity Research. - 2003. - Vol. 11(11). - Р. 1278-1289.
5. The ACCORD Study Group and 1. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes // N. Engl. J. Med. - 2010. - DOI: 10.1056/NEJMoa1001288.
6. ACCORD Study Group // N. Engl. J. Med. - 2010. - March. 14.
7. Beulens J.W., Patel A., Vingerling J.R., et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial // Diabetologia. - 2009. - 52. - Р. 2027-2036.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - Р. 837-853. (Erratum, Lancet 1999; 354: 602.)
9. UK Prospective Diabetes Study (UKPDS) Group. Effects of blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34) // Lancet. - 1998. - 352 (9131). - Р. 854-865.
10. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38) // British Medical Journal. - 1998. - 317. - Р. 703-713.
11. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials // BMJ. - 2006. - May 13, 332. - Р. 1115-1124.
12. American Diabetes Association. Standards of Medical Care in Diabetes: Dislipidemia Management // Diabetes Care. - 2007. - 30 (Suppl 1). - S4-S41.
13. Irons B.K., Kroon L.A. Lipid Management with Statins in Type 2 Diabetes Mellitus. The Annals of Pharmacotherapy. - 2005. - 39, № 10. - Р. 1714-1718.
14. Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians // Ann Intern. Med. - 2004. - 140. - Р. 644-649.
15. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate // Am. J. Cardiol. - 2008. - 102(12A). - 34L-40L.
16. Keech A.C., Mitchell P., Summanen P.A. et al., for the FIELD study investiga- tors. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial // Lancet. - 2007. - 370 (9600). - P.1687-1697.
17. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR . agonist, in traumatic brain injury // J. Neurotrauma. - 2007. - 24. - Р. 1119-1131.
18. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR. agonist, in traumatic brain injury // Diabetes care. - 2009. - vol. 32, № 8, august.
19. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.
20. Kushwin Rajamani, Peter G. Colman, Li Ping Li, James D. Best, Merryn Voysey, Michael C. D'Emden, Markku Laakso, John R. Baker, Anthony C. Keech, on behalf of the FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
21. Sergio Fazio Cardiovasc Drugs Ther June 2009.Vol 23(3):235-241
22. Rajamani K et al. Lancet. 2009;373:1780-8
23. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.
24. ESC/EASD Guidelines. Eur Heart J 2007; P. 28:88-136.
25. Home P et al. BMJ 2008; 336; P. 1306-8.
26. American Diabetes Association. Diabetes Care. 2008;31(suppl 1): S12-S54.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106: P. 3143-421.
Review
For citations:
Demidova T.Yu. Vascular complications of type 2 diabetes mellitus beyond the reach of glycemic control. Diabetes mellitus. 2010;13(3):111-116. (In Russ.) https://doi.org/10.14341/2072-0351-5498
Views:
6659
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
